New biodiagnostic technology launches at USF campus

By Garrett Ralston

TAMPA, FL – Protean BioDiagnostics launched a groundbreaking research program on the University of South Florida’s Connect campus Monday.

Associates of the company and colleagues gathered at the campus atrium to get a private and firsthand look at an emerging cancer treatment technology in its infant stage.

The Protean approach will seek to simplify cancer treatment technology by creating a one-stop program to address pathology review, testing, and data management in a scalable format.

Revolutionized technology and practices exist but oncologists and patients living in areas with limited laboratory resources are unable to benefit from them. Protean will be a conduit between this technology and its customers.

“New therapies and diagnostics have created an unmet need in the cancer treatment field,” said Anthony Magliocco M.D., Founder and President of Protean BioDiagnostics. “We’re creating a service that will package and manage these technologies to specifically meet that need.”

Anthony Magliocco M.D., Founder and President of Protean BioDiagnostics, speaks to colleagues and associates during a private tour of Protean’s new lab facility at the USF Connect campus Monday.